Teresa I. Ng

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Stefan Zeuzem, Graham R. Foster, Stanley Wang et al. · New England Journal of Medicine · 2018 · 426 citations · Full text

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Paul Y. Kwo, Fred Poordad, Armen Asatryan et al. · Journal of Hepatology · 2017 · 296 citations · Full text

Diagnostic Virology, Hepatology, Hepatitis C +9

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Tarik Asselah, Kris V. Kowdley, Neddie Zadeikis et al. · Clinical Gastroenterology and Hepatology · 2017 · 221 citations · Full text

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

Fred Poordad, Franco Felizarta, Armen Asatryan et al. · Hepatology · 2017 · 200 citations · Full text

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

Jürgen K. Rockstroh, Karine Lacombe, Rolando M. Viani et al. · Clinical Infectious Diseases · 2018 · 144 citations · Full text